Navigation Links
Rafarma Pharmaceuticals, Inc. Achieves Full Certification

Sandy, UT (PRWEB) December 17, 2012

Rafarma Pharmaceuticals, Inc. (the ”Company”) OTC symbol “APKND” announced that its manufacturing and packaging facility in Lipetsk, Russia was fully licensed last November 9th and exhibited by GMP (“Good Manufacturing Practices”) Certificate # 109489 7000-430 (see:

The facility is ISO 9001 and IHC Q 10 compliant. These internationally recognized certifications allow sales and distribution of all permitted products throughout Europe and all nations that are a party to the above standards. The manufacturing facility is currently operating at 30% capacity during its “start-up” phase, and is expected to reach full production during the second quarter of 2013.

With the resignation of Vladimir Bondar as Director and President and Natalia Leonidovna Stupina as Director and CFO due to other commitments, the Company appointed Mr. Sergey Brusnitsin as its new Director and CFO. Mr. Brusnitsin earned his PhD in Economics from the Moscow Institute of Economics and was formerly the director of the Federal Revenue Service of Russia. He has been affiliated with the Company in several capacities throughout its development phase. Mr. Alexander Ageev continues to function as Director, Secretary/Treasurer and Mr. David Anderson will remain as Director and CEO and perform the function of President until the first annual meeting, now scheduled for March 1, 2013.

With expended development costs in excess of $200 million, and expected first year revenue expectations exceeding $100 million, and an excellent product portfolio, the Company is expected to be a leading supplier of pharmaceuticals in the years to come.

The new OTC trading symbol for the Company will be announced by FINRA on January 2, 2013 and be effective January 3, 2013.

Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to: the impact of economic, competitive and other factors affecting the Company and its operations, markets, product, and distributor performance.

Media Contact: Dave Anderson, +1 801 210 7135, info (at) rafarma (dot) com

Rafarma Pharmaceuticals, Inc.,
SOURCE: Rafarma Pharmaceuticals, Inc.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Auxilium Pharmaceuticals, Inc. to Present At The Oppenheimer 23rd Annual Growth Conference
2. Ampio Pharmaceuticals, Inc. (AMPE) announces appointment of Josh Disbrow as Chief Operating Officer effective December 15, 2012
3. OncoGenex Pharmaceuticals, Inc. Provides Clinical Development Update and Reports Financial Results for Third Quarter 2012
4. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2012 Financial Results
5. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess of $100,000 Investing In Keryx Biopharmaceuticals, Inc. To Contact the Firm
6. FierceBiotech Names Enanta Pharmaceuticals, Inc. a Fierce 15 Winner
7. Auxilium Pharmaceuticals, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference
8. MAP Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
9. Auxilium Pharmaceuticals, Inc. to Present At The JMP Securities 2012 Healthcare Conference
10. Auxilium Pharmaceuticals, Inc. to Present at the Jefferies 2012 Global Healthcare Conference
11. Silence Therapeutics Partner, Quark Pharmaceuticals, Extends its Agreement With Pfizer to Develop one of Its Compounds Containing Silences AtuRNAi in a New Indication
Post Your Comments:
(Date:10/8/2015)... MADISON, N.J. , Oct. 8, 2015  Genetic ... guidelines may aid the identification of more couples at ... to a study presented today at the 2015 American ... through October 10 in Baltimore, Maryland ... from Quest Diagnostics (NYSE: DGX ) are presenting ...
(Date:10/8/2015)... 2015 .   ... Goldman Small Cap Research, a stock market ... microcap sectors, announced today that it has published ... Inc. (OTCQB - PMCB), a publicly traded, clinical ... treatments for cancer and diabetes. To view the ...
(Date:10/8/2015)...  The ALS Association, in partnership with Prize4Life, is ... revolutionize communication technology solutions for people living with ALS. ... (amyotrophic lateral sclerosis) is a progressive neurodegenerative disease that ... spinal cord. Eventually, people with ALS lose the ability ... to total paralysis and death within two to five ...
(Date:10/8/2015)... , ... October 08, 2015 , ... Talon Innovations, a ... Aerospace and other technology-driven industries, announces that it is one of three finalists for ... Midsize Company.” On Thursday, September 25 Talon Innovations was recognized as a nominee ...
Breaking Biology Technology:
... Verenium Corporation (Nasdaq: VRNM ), a leading ... of high-performance enzymes, today reported a summary of recent ... and nine months ended September 30, 2011. ... the first nine months of this year," said James ...
... Nov. 10, 2011 Theravalues, a Japan ... impacts positively on the prevention of heart failure and ... the human clinical trial started with the registration in ... Organization Kyoto Medical Center and University of Shizuoka, Japan, ...
... Kluwer Pharma Solutions, a leading provider of scientific information ... to investors through Bloomberg Tradebook,s Independent Research Provider (IRP) ... in Thought™, Wolters Kluwer Pharma Solutions, research ... pharmaceutical drugs and medical devices. ...
Cached Biology Technology:
(Date:9/10/2015)... Report Details The global wearable ... previous expectations of revenues, consumer adoption and even technological ... which wearables begin to achieve that mass market acceptance ... reasons is the entrance of Apple to the SmartWatches ... but the overall size of the wearable technology market. ...
(Date:9/9/2015)... , Sept. 9, 2015  NuData Security ... and solution-based milestones, furthering the company,s commitment to ... online fraud. NuData Security,s online fraud ... the company,s growth cycle. The product combines continual ... determine good user behavior from fraudulent behavior, allowing ...
(Date:9/2/2015)... Sept. 2, 2015 About hand geometry biometrics ... banks, government organizations, telecommunication and hospitals as well as ... badges, and numeric keypads are used to prevent unauthorised ... palm and fingers of an individual, width of the ... with infrared light and reflectors can be used for ...
Breaking Biology News(10 mins):
... School of Medicine (BUSM) have found a link ... HIV-infected persons. The study appears online in the ... Deficiency Syndromes., Alcohol use is common among HIV-infected ... has been examined in in-vitro, animal and human ...
... Pacific Northwest National Laboratory,have discovered a way to ... creation of a portable biosensor that can address ... nerve agents, the need to quickly distinguish between ... The sensor components resemble a pregnancy test ...
... biological systems engineering, is leading the team of ... Sciences ( ) at Virginia Tech ( ... convert poultry litter into bio-oil, providing an economical ... issues. Agblevor will present the research during ...
Cached Biology News:
... The high-performance triple quadrupole 1200L sets ... today's cost-conscious environment - incorporating the ... for all liquid chromatography analytical needs. ... interface and the Transmission Quadrupole Analyzer ...
C1-inhibitor (C1-INH)...
... ATP-Free using Mo Bio luciferase assay. Mo Bio ... that will allow you to certify your products ... enable you to deliver them to your customers ... detection limit is 3.5 x 10-12 /l, which ...
Choriongonadotropin (human, hCG)...
Biology Products: